Drug Profile
MT 0814
Alternative Names: MT-0814Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Eye disorder therapies; Small molecules
- Mechanism of Action CCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Wet age-related macular degeneration
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Wet age-related macular degeneration in Japan (PO)
- 06 Apr 2021 MT 0814 is still in phase II trial for Wet age-related macular degeneration in USA (PO) (NCT03869684)
- 24 Apr 2020 Senju Pharmaceutical terminates a phase II trial in Wet age-related macular degeneration in USA (PO) due to safety reasons (NCT03869684)